Public company, workplace, funding, and market signals
Updated Aug 5, 2026
Hims & Hers Health, Inc. (NYSE: HIMS) is a consumer-first digital health and telehealth platform. It connects customers with licensed providers through online intake and asynchronous messaging (with live care in some jurisdictions), then—when clinically appropriate—provides personalized prescription and over-the-counter treatments shipped through pharmacy partners and company-operated/affiliated fulfillment. The platform covers sexual health, hair care, skincare, weight loss, mental health, diagnostics and related wellness categories.
Primary product
A direct-to-consumer telehealth platform combining online clinical intake/provider care, personalized treatment recommendations, prescription and OTC products, pharmacy fulfillment, and recurring delivery subscriptions.
Founded
2017
Headquarters
2269 Chestnut Street, #523, San Francisco, CA 94123, United States
Team size
1,100+ publicly stated on careers page; 1,637 employees as of December 31, 2024 in the 10-K
Work style
Remote
Industry
Digital health / telehealth
Sub-industry
Consumer health technology, virtual care, direct-to-consumer prescription and wellness products
Offices
Business model
Stage
Public company; post-IPO financing stage
Latest round
Convertible senior notes · May 2025
Latest amount
$870M
May 2025
Jan 2021 · Oaktree Acquisition Corp. II
Leadership
Andrew Dudum
Co-founder and Chief Executive Officer
Soleil Boughton
Chief Legal Officer and Corporate Secretary
Yemi Okupe
Chief Financial Officer
Mike Chi
Chief Operating Officer / Chief Commercial Officer (company pages vary by timing)
Dr. Patrick Carroll
Chief Medical Officer
Dan Kenger
Chief Design Officer
Mo Elshenawy
Chief Technology Officer
Dheerja Kaur
Chief Product Officer
Deb Autor
Chief Policy Officer
Founders
Hilary Coles
Co-founder
Remote-first, autonomy-oriented and growth-minded, with virtual team-building, monthly all-hands, executive fireside chats, manager training, development and feedback programs, and an emphasis on diverse lived experiences and inclusive customer-centered work.
Work style
Remote
Compensation
The company advertises competitive salary bands, stock options/equity, 401(k) matching and an employee stock purchase plan. Specific role-level compensation and sponsorship terms vary and were not established from the retrieved public evidence.
Benefits
Pricing
Primarily self-pay, subscription-based recurring billing for medications/products and care; also offers one-time purchases. The company does not generally accept third-party insurance or government payors. Public pricing varies by condition, medication, cadence and eligibility; an independent 2025 comparison reported entry subscriptions around $20/month for some offerings.
Differentiators
Estimated revenue
Approximately $2.35B reported FY2025 revenue; approximately $2.8B-$3.0B company guidance for FY2026, so a reasonable current annual range is $2.3B-$3.0B.
Estimated monthly visits
6.5M
The FTC, Utah and California sued Hims & Hers alleging deceptive billing/cancellation practices and unlawful sharing of sensitive health information with advertising platforms. These are allegations, not adjudicated findings; Hims reportedly characterized the suit as baseless.
SourceHims & Hers completed/acquired Eucalyptus, according to industry deal databases and company 2026 materials; the transaction expands international operations, including Japan. Deal terms were not established from the retrieved official source.
SourceFederal Trade Commission · Jul 2026
FTC and state partners sued Hims & Hers over alleged privacy, billing and cancellation practices.
Hims & Hers investor relations · May 2026
Q1 revenue was approximately $608M, subscribers approximately 2.584M, and FY2026 revenue guidance was raised to $2.8B-$3.0B.
Hims & Hers investor relations · Feb 2026
The company reported FY2025 revenue growth and described international expansion, acquisitions and technology investment.
Hims & Hers investor relations · May 2025
102 jobs at Hims & Hers
Jan 2019 · Redpoint Ventures
Jun 2018 · Redpoint Ventures
Nov 2017 · Thrive Capital
Jack Abraham
Co-founder / Atomic incubator co-founder
Joe Spector
Co-founder
Technology
Customers
Competitors
The company pivoted U.S. weight-loss strategy toward branded GLP-1 medications and limited compounded GLP-1 access, recording restructuring-related costs and warning of margin pressure.
The company priced $870M of zero-coupon convertible notes to support expansion, acquisitions, AI, diagnostics and personalized care.